Brussels/Niel (Belgium), 4 March 2019 - eTheRNA immunotherapies, a clinical-stage company developing cancer immunotherapies based on its proprietary mRNA TriMix platform, announces the completion of the high-dose cohort of its Phase 1b study (E011-MEL) evaluating ECI-006 (TriMix with tumor specific antigens) in an adjuvant setting in melanoma patients after surgical removal of lesions. The E011-MEL study confirms the feasibility of developing mRNA immunotherapy for direct injection intranodally, in addition to a previously used dendritic cell infusion-based approach.
The E011-MEL Phase 1b study was designed to evaluate intranodal (injection into the inguinal lymph nodes) administration of ECI-006 in adjuvant melanoma patients. ECI-006 is a TriMix-based immunotherapy boosted with mRNA encoding melanoma tumor-specific antigens. The study comprises a low-dose and a high-dose cohort, each enrolling 10 patients. Investigative centres were in Belgium and Spain. The objective of the study is to assess safety and tolerability of mRNA administered intranodally and to seek evidence of immune-stimulation.
Brussels/Niel (Belgium), 12 February 2019 - VUB, the Vrije Universiteit Brussel, and eTheRNA immunotherapies, a clinical-stage company developing cancer immunotherapies based on its proprietary mRNA-based TriMix platform, announce the recruitment of the first patient for a collaborative TriMix-BRE study to investigate the effect of the TriMix product as neo-adjuvant treatment (treatment before planned surgery) for breast cancer patients. The study will deliver mRNA via intratumoral injection in patients with non-metastatic breast cancer before planned surgery and will recruit patients with resectable breast cancer irrespective of subtype of breast cancer.
Dr. Marian Vanhoeij, Head of the Breast Clinic of the University Hospital, UZ Brussel and principal investigator of this investigator-initiated study: “We are pleased to contribute to the further clinical development of the TriMix-platform, which has been developed at our university and is now the backbone of eTheRNA immunotherapies, a spin-off from the VUB university. While the proof of concept for the TriMix platform has been delivered in multiple studies involving melanoma patients, we are convinced of the potential for TriMix in other therapeutic areas including breast cancer. In the TriMix-BRE study, a total of 36 breast cancer patients will be enrolled at the Brussels university hospital (UZ Brussel). The TriMix product will be administered 3 times in the tumor of the patients before surgical removal or before start of neo-adjuvant chemotherapy.”
Niel (Belgium), 8 October 2018 - eTheRNA immunotherapies, a clinical-stage company developing novel cancer immunotherapies based on its proprietary mRNA-based TriMix platform, announces the opening of a state-of-the-art mRNA manufacturing facility enabling the production of mRNA immunotherapies.